Skip to content
Therapy But Better – Lifestyle
Author:
TenNor Therapeutics (Suzhou) Limited
TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection
September 10, 2026